Can-Fite BioPharma CANF Stock
Can-Fite BioPharma Price Chart
Can-Fite BioPharma CANF Financial and Trading Overview
| Can-Fite BioPharma stock price | 3.11 USD |
| Previous Close | 3.35 USD |
| Open | 3.34 USD |
| Bid | 0 USD x 10000 |
| Ask | 0 USD x 20000 |
| Day's Range | 3.16 - 3.32 USD |
| 52 Week Range | 2.83 - 23.4 USD |
| Volume | 47.47K USD |
| Avg. Volume | 1.13M USD |
| Market Cap | 6.94M USD |
| Beta (5Y Monthly) | 0.028 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
CANF Valuation Measures
| Enterprise Value | 5.41M USD |
| Trailing P/E | N/A |
| Forward P/E | -12.461539 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.140375 |
| Price/Book (mrq) | 0.758427 |
| Enterprise Value/Revenue | 13.37 |
| Enterprise Value/EBITDA | -0.546 |
Trading Information
Can-Fite BioPharma Stock Price History
| Beta (5Y Monthly) | 0.028 |
| 52-Week Change | -85.27% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 23.4 USD |
| 52 Week Low | 2.83 USD |
| 50-Day Moving Average | 3.19 USD |
| 200-Day Moving Average | 6.58 USD |
CANF Share Statistics
| Avg. Volume (3 month) | 1.13M USD |
| Avg. Daily Volume (10-Days) | 24.65K USD |
| Shares Outstanding | 2.14M |
| Float | 4.29M |
| Short Ratio | 0.09 |
| % Held by Insiders | 0% |
| % Held by Institutions | 6.54% |
| Shares Short | 116.56K |
| Short % of Float | 5.46% |
| Short % of Shares Outstanding | 5.43% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2488.67% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -66.74% |
| Return on Equity (ttm) | -178.23% |
Income Statement
| Revenue (ttm) | 405K USD |
| Revenue Per Share (ttm) | 0.49 USD |
| Quarterly Revenue Growth (yoy) | -43.29% |
| Gross Profit (ttm) | 405K USD |
| EBITDA | -9926000 USD |
| Net Income Avi to Common (ttm) | -9828000 USD |
| Diluted EPS (ttm) | -10.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.54M USD |
| Total Cash Per Share (mrq) | 1.99 USD |
| Total Debt (mrq) | 71K USD |
| Total Debt/Equity (mrq) | 1.27 USD |
| Current Ratio (mrq) | 3.457 |
| Book Value Per Share (mrq) | 4.272 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8949000 USD |
| Levered Free Cash Flow (ttm) | -4985750 USD |
Profile of Can-Fite BioPharma
| Country | United States |
| State | N/A |
| City | Ramat Gan |
| Address | 26 Ben Gurion Street |
| ZIP | 5257346 |
| Phone | 972 3 924 1114 |
| Website | https://www.canfite.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Q&A For Can-Fite BioPharma Stock
What is a current CANF stock price?
Can-Fite BioPharma CANF stock price today per share is 3.11 USD.
How to purchase Can-Fite BioPharma stock?
You can buy CANF shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Can-Fite BioPharma?
The stock symbol or ticker of Can-Fite BioPharma is CANF.
Which industry does the Can-Fite BioPharma company belong to?
The Can-Fite BioPharma industry is Biotechnology.
How many shares does Can-Fite BioPharma have in circulation?
The max supply of Can-Fite BioPharma shares is 2.14M.
What is Can-Fite BioPharma Price to Earnings Ratio (PE Ratio)?
Can-Fite BioPharma PE Ratio is now.
What was Can-Fite BioPharma earnings per share over the trailing 12 months (TTM)?
Can-Fite BioPharma EPS is -10.75 USD over the trailing 12 months.
Which sector does the Can-Fite BioPharma company belong to?
The Can-Fite BioPharma sector is Healthcare.
Can-Fite BioPharma CANF included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NYSE American Composite Index XAX | 8750.58 USD — |
-0.14
|
— — | 8749.41 USD — | 8844.17 USD — | — - | — — |
- {{ link.label }} {{link}}